Risk factors
Agios Pharmaceuticals (AGIO) risk factors
Item 1A of every Agios Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks9 new8 dropped29 reworded
Agios added new risks covering U.S. tariffs, clinical trial disruptions, and regulatory exclusivity challenges for its drug pipeline.
Filed Feb 12, 2026 - FY2024 10-K risk factors54 risks
Commercializing PYRUKYND and advancing clinical candidates dominate this risk profile. Dependence on third-party manufacturers, clinical sites, and collaborative partners is critical. Intellectual property protection and regulatory pricing pressures heavily influence future viability.
Filed Feb 13, 2025